| Symbol | AZN |
|---|---|
| Name | ASTRAZENECA PLC |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | - |
| Address | 10179 United States NY 383 Madison Avenue Floor 11 |
| Telephone | +44 20 3749 5000 |
| Fax | — |
| — | |
| Website | http://www.astrazeneca.com |
| Incorporation | GB |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ;NYSE |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0000901832 |
| Description | AstraZeneca is a global science-led biopharmaceutical company that focuses on the discovery development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive open and collaborative. This approach runs through all that we do. We focus on three main therapy areas Oncology Cardiovascular & Metabolic Disease CVMD and Respiratory and we are also selectively active in the areas of autoimmunity neuroscience and infection. Additional info from NASDAQ: |
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
Read moreTozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
Read moreNew Form 25-NSE - ASTRAZENECA PLC <b>Filed:</b> 2026-04-08 <b>AccNo:</b> 0000876661-26-000343 <b>Size:</b> 3 KB
Read moreIMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer
Read more